Dominic Reynolds
Chief Scientific Officer Remix Therapeutics
As Chief Scientific Officer, Dominic is stoked to be a part of building Remix from the ground up, leading the design and synthesis of compounds to reprogram RNA processing and forge a path to the clinic. Dominic has extensive experience in the biotech space and building successful biotech companies. Recent positions include drug discovery consultancy to two seed-stage companies at Third Rock Ventures and VP, Head of Chemistry at H3 Biomedicine, a company he joined on day one. Prior to that Dominic worked at Forma Therapeutics, where he also joined on the first day, and he started his career at Millennium Pharmaceuticals. He received his PhD in synthetic chemistry from the University of Cambridge and conducted postdoctoral training at Harvard University where he focused on natural product synthesis.
Seminars
- REM-422, orally available small molecule targeting MYB, is well-tolerated at RP2D (24mg)
- REM-422 shows anti-tumor activity in biomarker positive R/M ACC at RP2D
- REM-422 has indication expansion opportunities in additional solid tumors and hematological malignancies
Identifying RNA targets that are both biologically meaningful and chemically tractable remains one of the biggest bottlenecks in RNA-targeted drug discovery. Many RNA regions are capable of binding small molecules, but only a subset controls diseaserelevant biology in a way that can support a therapeutic hypothesis.
Join RNA biologists, screening scientists, translational researchers, and discovery
teams to explore practical strategies for:
- Identifying which RNA transcripts, structures and regulatory elements are suitable for small-molecule intervention
- Moving beyond one-at-a-time target discovery with scalable screening and functional assay approaches
- Using chemical probing to distinguish dynamic RNA structures from functionally important conformational switches
- Matching each RNA target to the most appropriate therapeutic hypothesis, from splice modulation to direct binding, degradation or translational inhibition
- Learning from screening approaches that failed to generate actionable targets, functional hits or reliable discovery decisions
